Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 700 participants.

Also called NCT03907046

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 700 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03907046
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03907046. Randomized; quadruple masking; primary purpose prevention. Start 2020-01-28 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Acronym
ASPIRE
Condition
Intracerebral Hemorrhage
Intervention (Drug)
Apixaban
Intervention (Drug)
Aspirin
Lead sponsor
Yale University (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03907046
Content hash
57f022cb084e11fa8cdc9a8eacdcb34d2d233b795cd12b813f0d12ba95cc6299